Document is current
Any future updates will be listed below
-
Authors
Jackson, Lisa A.
Coler, Rhea N.
Deye, Gregory A.
Carter, Darrick
Gray, Sean A.
Pecor, Tiffany
Davis, Jenn
Larsen, Sasha E.
Posavad, Christine M.
Cox, Catherine
Watanabe, Amy
Lundeen, Jordan S.
Gill, Ranjodh
Kalyanasundaram, Aravindan
Siddiqui, Afzal A.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI148684)
National Institute of Allergy and Infectious Diseases (UM1AI148684)
National Institute of Allergy and Infectious Diseases (UM1AI148684)
National Institute of Allergy and Infectious Diseases (UM1AI148684)
National Institute of Allergy and Infectious Diseases (UM1AI148684)
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 21 August 2025
First Online: 24 November 2025
Competing interests
: G.A.D. is currently an employee of AstraZeneca. D.C. is a shareholder in PAI Life Sciences Inc. which holds a license to the SchisoShield® product.All other authors declare no competing interests.
